1.Comprehensive clinical evaluation of phosphate-lowering drugs in the treatment of chronic kidney disease with hyperphosphatemia
Lu LIU ; Cangsang SONG ; Xingde LI ; Chunni HAN ; Run SUN ; Chunjie YU ; Yalin LI
China Pharmacy 2026;37(14):1918-1924
OBJECTIVE To conduct a comprehensive clinical evaluation of phosphate-lowering drugs in the treatment of chronic kidney disease (CKD) with hyperphosphatemia, and to provide evidence-based support for clinical drug decision-making. METHODS Relevant studies meeting the inclusion and exclusion criteria were retrieved, a comprehensive evaluation of efficacy, safety and economics was conducted based on existing study results. Innovation was analyzed from three aspects including filling the clinical gap, and suitability was assessed from two aspects including technical suitability. Accessibility was evaluated based on the survey data from 37 medical institutions in Kunming, combined with information from the National Reimbursement Drug List and national centralized drug procurement. RESULTS A total of 10 meta-analyses and 2 pharmacoeconomic studies were included. In terms of efficacy, all three categories of phosphate-lowering drugs (calcium-based phosphate binders, non-calcium-based phosphate binders, sodium-hydrogen exchanger 3 inhibitors) effectively reduced serum phosphorus levels. Calcium-based phosphate binders elevated serum calcium levels more significantly; sevelamer was superior to calcium-based phosphate binders in reducing intact parathyroid hormone levels; iron-based phosphate binders improved iron metabolism and anemia-related indicators. In terms of safety, iron-based phosphate binders had the highest incidence of gastrointestinal adverse reactions, followed by lanthanum carbonate. In terms of economics, sevelamer demonstrated economic advantages over calcium-based phosphate binders and lanthanum carbonate. In terms of innovation, non-ca lcium-based phosphate binders addressed the clinical limitation of hypercalcemia associated with calcium-based phosphate binders; iron-based phosphate binders met the treatment needs of patients with comorbid iron deficiency anemia; tenapanor exhibited an innovative phosphorus-lowering mechanism. In terms of suitability, all three categories showed good suitability in various aspects. In terms of accessibility, sevelamer had the highest availability rate, while tenapanor was not yet available in medical institutions. All three categories have been included in the National Reimbursement Drug List ; the prices of lanthanum carbonate and sevelamer decreased substantially following centralized procurement with improved affordability. CONCLUSIONS For CKD patients with hyperphosphatemia, non-calcium-based phosphate binders are preferred, among which sevelamer is recommended as the first-line choice. Lanthanum carbonate may be considered for patients with gastrointestinal intolerance; iron-based phosphate binders are preferred for patients with comorbid iron deficiency anemia; tenapanor may be considered for patients with poor response to or intolerance of conventional regimens; calcium-based phosphate binders are not recommended as long-term first-line therapy.
2.The role of bile acid dynamics in inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease
Si-Rui Yu ; Run Sun ; Mei-Ya Shi ; Mei Yang ; Kun Chen ; Qiong Pan ; Ling Zhao ; Ming-Yue Wu ; Jin Chai
Liver Research 2026;10(1):35-50
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is higher among individuals with inflammatory bowel disease (IBD) than in the general population. Emerging evidence indicates that the development of MASLD in patients with IBD may occur independently of traditional metabolic risk factors, suggesting a unique pathophysiological mechanism distinct from conventional MASLD pathways. Bile acids (BAs), which act as critical signaling molecules in enterohepatic circulation, play an essential role in maintaining gastrointestinal homeostasis through bidirectional gut–liver axis communication. These molecules are increasingly recognized as pivotal regulators in the progression of both MASLD and IBD. While previous studies have characterized the dynamics of BA in blood or fecal samples under both conditions, a comprehensive understanding of their metabolic profiles and the associated interactions within the gut–liver axis is still lacking. This review synthesizes current evidence from studies employing BA metabolomics to investigate IBD and MASLD. By focusing on BA signatures, we summarize conserved alterations between these two conditions and their potential mechanisms of disease progression. Our review advances understanding of BA-mediated pathways in IBD and MASLD, providing a foundation for assessing their roles in contributing to the pathogenesis of MASLD in patients with IBD.
3.Qishen Liuwei Prescription Combined with Conventional Antihypertensive Therapy in Intervention of Senile Primary Hypertension Complicated with Frailty: A Randomized Controlled Trial
Hanxi CHAN ; Yanran HUI ; Lijun HUANG ; Linbo YU ; Huali XIAO ; Kun ZHOU
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(18):162-170
ObjectiveTo evaluate the clinical efficacy and safety of the Qishen Liuwei presoription for senile hypertension complicated with frailty (of Qi deficiency and blood stasis pattern, or deficiency of both spleen and kidney pattern). MethodsA single-center, randomized controlled clinical trial design was employed in this study. Sixty-four eligible patients, treated at the Cardiology Outpatient Clinic of Dongfang Hospital, Beijing University of Chinese Medicine between June 2024 and February 2025, were randomly allocated into an observation group or a control group, with 32 patients in each group. Both groups received standard conventional antihypertensive therapy, while the observation group additionally received the Qishen Liuwei Formula (one dose per day, in separate servings in the morning and evening). For both groups, a treatment course consisted of 4 weeks, followed by a 2-month follow-up period. Then, the primary indicator (Fried frailty phenotype scores), along with secondary indicators including traditional Chinese medicine (TCM) syndrome scores and changes in blood pressure were observed before and after treatment. ResultsRegarding Fried frailty phenotype scores, the observation group exhibited significantly improved grip strength, 4.57 m walk time, the duration of weekly walks, ''effort required for any activity'', and ''inability to walk forward'' after treatment, while only the latter two indicators were significantly improved in the control group (P<0.05). Compared with the control group, the observation group demonstrated significantly superior improvement in the duration of weekly walks, ''effort required for any activity'', and frailty (P<0.05). For total TCM syndrome scores, both groups displayed significantly decreased total TCM syndrome scores (P<0.05) after treatment, and the decrease was more significant in the observation group (P<0.05). Regarding office blood pressure, both groups showed significantly decreased diastolic blood pressure and mean arterial pressure after treatment, while the observation group also showed significantly decreased systolic blood pressure (P<0.05). During treatment, one case of facial rash occurred in the observation group, representing an adverse reaction rate of 3.13% (1/32). The rash resolved one week after discontinuation of medication. No adverse reactions occurred in the control group during treatment. No statistically significant difference was observed in the incidence of adverse reactions between the two groups. ConclusionFor senile hypertension complicated with frailty, the Qishen Liuwei presoription effectively improves physical activity, muscle strength, frailty-related symptoms, and TCM syndrome remission. When combined with Western medicine, the Formula contributes to stable blood pressure control and demonstrates a favorable clinical safety profile, indicating its clinical application potential.
4.Dr. Edmunds Grey Dimond: first foreign doctor to visit China for investigating acupuncture anesthesia.
Run HONG ; Zheng SUN ; Zilong ZHU ; Kuang YU ; Haitian SUN ; Jianbin ZHANG
Chinese Acupuncture & Moxibustion 2025;45(5):688-693
The international dissemination of Chinese acupuncture represents a successful model of medical and cultural exchange between the East and the West, as well as an exemplary case of Chinese culture going global. In 1971, following the announcement by Xinhua News Agency that "acupuncture anesthesia technology had achieved success", American medical educator Professor Edmunds Grey Dimond became the first foreign doctor to visit China for an investigation of acupuncture anesthesia. His efforts significantly contributed to the promotion of Chinese acupuncture within western medical communities. From the perspective of acupuncture humanities, this article reviews and analyzes Dimond's academic background, his journey to study acupuncture anesthesia in China, and his unique insights into acupuncture, exploring how his open-minded and objective approach facilitated the acceptance and dissemination of acupuncture anesthesia and acupuncture techniques in the West.
China
;
Humans
;
History, 20th Century
;
Acupuncture Therapy/history*
;
Acupuncture/history*
;
Acupuncture Analgesia/history*
;
History, 21st Century
5.Cost-effectiveness of angiographic quantitative flow ratio-guided coronary intervention: A multicenter, randomized, sham-controlled trial.
Yanyan ZHAO ; Changdong GUAN ; Yang WANG ; Zening JIN ; Bo YU ; Guosheng FU ; Yundai CHEN ; Lijun GUO ; Xinkai QU ; Yaojun ZHANG ; Kefei DOU ; Yongjian WU ; Weixian YANG ; Shengxian TU ; Javier ESCANED ; William F FEARON ; Shubin QIAO ; David J COHEN ; Harlan M KRUMHOLZ ; Bo XU ; Lei SONG
Chinese Medical Journal 2025;138(10):1186-1193
BACKGROUND:
The FAVOR (Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous Intervention in Patients with Coronary Artery Disease) III China trial demonstrated that percutaneous coronary intervention (PCI) lesion selection using quantitative flow ratio (QFR) measurement, a novel angiography-based approach for estimating fractional flow reserve, improved two-year clinical outcomes compared with standard angiography guidance. This study aimed to assess the cost-effectiveness of QFR-guided PCI from the perspective of the current Chinese healthcare system.
METHODS:
This study is a pre-specified analysis of the FAVOR III China trial, which included 3825 patients randomized between December 25, 2018, and January 19, 2020, from 26 centers in China. Patients with stable or unstable angina pectoris or those ≥72 hours post-myocardial infarction who had at least one lesion with a diameter stenosis between 50% and 90% in a coronary artery with a ≥2.5 mm reference vessel diameter by visual assessment were randomized to a QFR-guided strategy or an angiography-guided strategy with 1:1 ratio. During the two-year follow-up, data were collected on clinical outcomes, quality-adjusted life-years (QALYs), estimated costs of index procedure hospitalization, outpatient cardiovascular medication use, and rehospitalization due to major adverse cardiac and cerebrovascular events (MACCE). The primary analysis calculated the incremental cost-effectiveness ratio (ICER) as the cost per MACCE avoided. An ICER of ¥10,000/MACCE event avoided was considered economically attractive in China.
RESULTS:
At two years, the QFR-guided group demonstrated a reduced rate of MACCE compared to the angiography-guided group (10.8% vs . 14.7%, P <0.01). Total two-year costs were similar between the groups (¥50,803 ± 21,121 vs . ¥50,685 ± 23,495, P = 0.87). The ICER for the QFR-guided strategy was ¥3055 per MACCE avoided, and the probability of QFR being economically attractive was 64% at a willingness-to-pay threshold of ¥10,000/MACCE avoided. Sensitivity analysis showed that QFR-guided PCI would become cost-saving if the cost of QFR were below ¥3682 (current cost: ¥3800). Cost-utility analysis yielded an ICER of ¥56,163 per QALY gained, with a 53% probability of being cost-effective at a willingness-to-pay threshold of ¥85,000 per QALY gained.
CONCLUSION:
In patients undergoing PCI, a QFR-guided strategy appears economically attractive compared to angiographic guidance from the perspective of the Chinese healthcare system.
TRIAL REGISTRATION
ClinicalTrials.gov , NCT03656848.
Humans
;
Cost-Benefit Analysis
;
Percutaneous Coronary Intervention/methods*
;
Male
;
Female
;
Coronary Angiography/methods*
;
Middle Aged
;
Aged
;
Coronary Artery Disease/surgery*
;
Quality-Adjusted Life Years
;
Fractional Flow Reserve, Myocardial/physiology*
6.Sinisan, a compound Chinese herbal medicine, alleviates acute colitis by facilitating colonic secretory cell lineage commitment and mucin production.
Ya-Jie CAI ; Jian-Hang LAN ; Shuo LI ; Yue-Ning FENG ; Fang-Hong LI ; Meng-Yu GUO ; Run-Ping LIU
Journal of Integrative Medicine 2025;23(4):429-444
OBJECTIVE:
Ulcerative colitis is closely associated with intestinal stem cell (ISC) loss and impaired intestinal mucus barrier. Sinisan (SNS), a compound Chinese herbal medicine, has a long history in the treatment of intestinal dysfunction, yet whether SNS can relieve acute experimental colitis by modulating ISC proliferation and secretory cell differentiation has not been studied. Our study tested the effect of SNS against acute colitis and focused on the mechanisms involving intestinal barrier recovery.
METHODS:
Network pharmacology analysis and blood entry component analysis of SNS were used to explore the underlying mechanism by which SNS affects the acute dextran sulfate sodium (DSS)-induced murine colitis model. RNA-sequencing was used to demonstrate the mechanism. Further, reverse transcription-quantitative polymerase chain reaction, immunofluorescence staining, and alcian blue and periodic acid-Schiff staining were performed in vivo and in the colonic organoids to investigate the cell lineage differentiation-related mechanism of SNS. Furthermore, potential active ingredients from SNS were predicted by network pharmacology analysis.
RESULTS:
SNS dramatically suppressed DSS-induced acute colonic inflammation in mice. RNA-sequencing analysis revealed downregulation of inflammation and apoptosis-related genes, and upregulation of lipid metabolism and proliferation-related genes, such as Irf7, Pparα, Clspn and Hspa5. Additionally, ISC renewal and intestinal secretory cell lineage commitment were significantly promoted by SNS both in vivo and in vitro in colonic organoids, leading to enhanced mucin expression. Furthermore, potential active ingredients from SNS that mediated inflammation, lipid metabolism, proliferation, apoptosis, stem cells and secretory cells were predicted using a network pharmacology approach.
CONCLUSION
Our study shed light on the underlying mechanism of SNS in attenuating acute colitis from the perspective of ISC renewal and secretory lineage cell differentiation, suggesting a of novel therapeutic strategy against colitis. Please cite this article as: Cai YJ, Lan JH, Li S, Feng YN, Li FH, Guo MY, et al. Sinisan, a compound Chinese herbal medicine, alleviates acute colitis by facilitating colonic secretory cell lineage commitment and mucin production. J Integr Med. 2025; 23(4): 429-444.
Animals
;
Drugs, Chinese Herbal/therapeutic use*
;
Mice
;
Colon/pathology*
;
Mucins/metabolism*
;
Mice, Inbred C57BL
;
Cell Differentiation/drug effects*
;
Male
;
Colitis/metabolism*
;
Cell Lineage/drug effects*
;
Dextran Sulfate
;
Stem Cells/drug effects*
;
Disease Models, Animal
7.Effects of Hofmeister series ions on encapsulation efficiencies of three components in inclusion complex of volatile oils from Wenjing Decoction
Wen SHEN ; Zhuo-yuan LI ; Lin TAO ; Wei XIE ; Run SHI ; Yu-han CUI ; Wen LI ; Jun-song LI
Chinese Traditional Patent Medicine 2025;47(11):3571-3580
AIM To explore the effects of Hofmeister series ions on encapsulation efficiencies of cinnamaldehyde,paeonol,and ligustilide in inclusion complex of volatile oils from Wenjing Decoction.METHODS The volatile oils were extracted,after which the β-cyclodextrin inclusion complex was prepared,the thermal stability was evaluated,and encapsulation efficiencies and inclusion complex constants of various volatile components in Na2SO4,NaH2PO4,NaCl,NaI,NaSCN solutions were determined.RESULTS The β-cyclodextrin inclusion complex demonstrated good thermal stability within 10 d.After the addtion of Hofmeister series ions,various volatile components displayed increased encapsulation efficiencies and inclusion complex constants,and concentration-dependent manner was observable in the latter.CONCLUSION Hofmeister series ions can affect the binding affinities of volatile components and β-cyclodextrin in volatile oils from Wenjing Decoction,thus regulate their encapsulation efficiencies.
8.Effect of CYFIP1 on proliferation and apoptosis of colorectal cancer cell HT29
Fu-long YU ; Liang LI ; Hao QIANG ; Hui YUAN ; Song WANG ; Xiao-hu CHENG ; Run-ben JIANG ; Ya-ru YANG ; Zhi-ning LIU
Chinese Pharmacological Bulletin 2025;41(1):116-121
Aim To investigate the expression levels of cytoplasmic FMR1-interacting protein-1(CYFIP1)in colorectal cancer and assess the impact of CYFIP1 interaction on the proliferation and apoptosis of colorec-tal cancer cell HT29,along with its potential mecha-nisms.Methods Immunohistochemistry was em-ployed to assess CYFIP1 expression in 32 colorectal cancer tissues and adjacent tissues.Coexpressed genes were identified using the GEPIA2 website to predict potential correlations and binding sites.Following the construction of a siRNA-CYFIP1,alterations in cell proliferation,apoptosis,and levels of apoptosis-related proteins were evaluated through CCK-8 assay,Hoechst 33342/PI double staining assay,and Western blot a-nalysis,respectively.Results The immunohisto-chemical findings revealed a significantly elevated level of CYFIP1 expression in colorectal cancer tissues com-pared to paracancer tissues(P<0.05).The expres-sion of CYFIP1 did not show any correlation with age and gender,but exhibited associations with TNM stage and lymph node metastasis(P<0.05).A conserved TP53 binding site was predicted in the 3kbps DNA re-gion upstream of the CYFIP1 gene using GEPIA2,JASPAR databases,and rVista 2.0 promoter prediction software.Following transfection of HT29 cells with siRNA-CYFIP1,the clonogenesis and proliferation of cells significantly decreased(P<0.05).Additional-ly,the levels of cleaved caspase-3 were elevated,while the expression levels of caspase-3 and Bcl-2 were reduced after transfection with siRNA-CYFIP1(P<0.05),which might be related to the interaction be-tween CYFIP1 and TP53.Conclusions The upregu-lation of CYFIP1 in colorectal cancer is associated with TNM stage and lymph node metastasis.Upon silen-cing,CYFIP1 demonstrates the ability to suppress pro-liferation in HT29 cells and modulate the expression of apoptotic proteins.
9.Research Progress on the Mechanism of Action of Moxibustion in the Treatment of Essential Hypertension
Kuang YU ; Sai YING ; Zheng SUN ; Haitian SUN ; Run HONG ; Zilong ZHU ; Jianbin ZHANG
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(5):609-614
This paper systematically sorts out the historical evolution and modern research progress of moxibustion in the treatment of essential hypertension.It analyzes the development of moxibustion in the treatment of hypertension from early experience to the for-mation of theory,from clinical exploration,initial systematization of clinical research to the current development results,reflecting the scientific and innovative transformation of moxibustion in the treatment of essential hypertension.It reveals that moxibustion can achieve antihypertensive effects through multiple pathways,including neuron-body fluid regulation,renin-angiotensin-aldosterone system reg-ulation,cell signaling pathway regulation,vascular homeostasis,and immune system function regulation,emphasizing its internal con-sistency from macroscopic syndrome differentiation to microscopic mechanism.Through systematic integration,it can not only highlight the unique advantages of moxibustion in"multi-dimensional adjustment",but also provide a new perspective for breaking through the single-target limitation of current antihypertensive drugs.
10.Novel PAX1 mutation identified in autosomal dominant otofaciocervical syndrome 2 with new phenotypes
Ying CHEN ; Run YANG ; Nai′er LIN ; Qingxiong YU ; Xin CHEN ; Tianyu ZHANG ; Jing MA
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2025;60(7):815-823
Objective:To determine the diagnosis of microtia-associated syndrome through genetic testing.Methods:Peripheral venous blood samples were collected from members of a two-generation family with a syndrome associated with ear malformations (3 patients and 1 normal control). Pathogenic mutations were identified using whole exome sequencing analysis, Sanger sequencing validation, and bioinformatics analysis. Based on the genetic diagnosis and a review of the literatures, the patients′ clinical phenotypes were thoroughly evaluated to confirm the clinical diagnosis.Results:All three patients carried a novel heterozygous insertion mutation (c.1171_1172insGGCC: p.Pro391fs) in the paired box 1 ( PAX1) gene. This mutation showed genotype-phenotype co-segregation within the family and was predicted to be pathogenic. Consequently, the family was diagnosed with autosomal dominant otofaciocervical syndrome 2. The clinical phenotypes of the patients included not only ear malformations and conductive hearing loss but also branchial cleft fistula, preauricular fistula, bilateral facial asymmetry, spinal deformities, and short stature, which were major symptoms of otofaciocervical syndrome 2. Imaging also revealed previously unreported phenotypes, including parotid gland malformation and facial nerve dysplasia. Conclusion:The heterozygous insertion in PAX1 (c.1171_1172insGGCC: p.Pro391fs) found in this family causes otomandibular-cervical syndrome type 2 in an autosomal dominant manner, leading to congenital anomalies affecting external and middle ear, craniofacial region, and spine.


Result Analysis
Print
Save
E-mail